Werfen has received CE marking for its Aptiva antiphospholipid syndrome (APS) Immunoglobulin G (IgG) and Immunoglobulin M (IgM) reagents, meaning the in vitro diagnostics can now be used in the EU.
The reagents are immunoassays that use the company’s particle-based multi-analyte technology. Levels of anti-cardiolipin and anti-beta 2 glycoprotein 1 IgG and IgM autoantibodies in human serum and citrated plasma are semi-quantitively determined.
Go deeper with GlobalData
Patients with antiphospholipid syndrome have an increased risk of blood clots. Also known as Hughes syndrome, the autoimmune disorder is characterised by the presence of antiphospholipid antibodies. Spain-headquartered Werfen says its reagents can be used to diagnose primary and secondary antiphospholipid syndrome with the help of other laboratory findings.
Werfen’s vice-president of research and development Michael Mahler said: “Early diagnosis is crucial in preventing complications as well as unnecessary procedures and increased healthcare costs. Aptiva APS IgG and APS IgM deliver expanded information to clinicians to help with the diagnosis and management of patients with autoimmune diseases.”
In October 2023, Werfen received US Food and Drug Administration clearance for a reagent to help diagnose connective tissue disease. Also in the company’s Aptiva range is a celiac disease test.
See Also:
Aptiva can detect 19 CE-marked analytes, according to the company.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataWerfen revealed that it has more than 60 further analytes in the pipeline, with more autoimmune diseases being targeted.
Werfen saw revenue of €2.2bn ($2.4bn) in 2022, down 0.7% from 2021. The company has had to deal with the decline of Covid-19-related sales but has grown its core businesses: Hemostasis, Acute Care and Autoimmunity.
In late 2022, the company completed its acquisition of US-based in vitro diagnostics company Immucor.
According to a market model by GlobalData, Werfen owns 10% of a diverse haemostasis in vitro diagnostic market. Roche and Abbott have the highest shares of 18.9% and 17.9%, respectively. The global haemostasis tests market is expected to grow to $675m by 2033.
